^
BIOMARKER:

RAD51B mutation

i
Other names: RAD51 Paralog B, DNA Repair Protein RAD51 Homolog 2, RAD51 Homolog B, RAD51L1, R51H2, RAD51 Homolog B (S. Cerevisiae), RAD51 (S. Cerevisiae)-Like 1, RAD51-Like 1 (S. Cerevisiae), RAD51-Like Protein 1, RecA-Like Protein, Rad51B
Entrez ID:
Related biomarkers:
Phase 2
Shadia Jalal, MD
Recruiting
Last update posted :
10/06/2021
Initiation :
07/09/2019
Primary completion :
05/01/2022
Completion :
05/01/2023
BRCA1 • BRCA2 • ARID1A • CDK12 • RAD51B • BRIP1 • CHEK2 • FANCA • RAD51 • RAD51C • RAD51D • RAD54L • BARD1 • NBN • GEN1
|
BRCA1 mutation • BRCA2 mutation • ATM mutation • PALB2 mutation • CDK12 mutation • BRIP1 mutation • RAD51D mutation • CHEK2 mutation • RAD51C mutation • FANCA mutation • RAD51B mutation • BARD1 mutation • RAD54L mutation • NBN mutation
|
Zejula (niraparib)
Phase 4
AstraZeneca
Active, not recruiting
Last update posted :
09/29/2021
Initiation :
09/28/2015
Primary completion :
04/17/2020
Completion :
09/20/2021
BRCA1 • BRCA2 • CDK12 • RAD51B • BRIP1 • CHEK2 • RAD51C • MUC16 • CHEK1 • RAD54L • BRCA • FANCL • PPP2R2A
|
BRCA1 mutation • BRCA2 mutation • CHEK2 mutation • RAD51B mutation • BARD1 mutation • BRCA mutation
|
Lynparza (olaparib)
Phase 1/2
National Cancer Institute (NCI)
Recruiting
Last update posted :
09/24/2021
Initiation :
09/20/2021
Primary completion :
03/01/2026
Completion :
03/01/2026
BRCA1 • BRCA2 • HRD • CDK12 • RAD51B • BRIP1 • CHEK2 • RAD51C • RAD51D • CHEK1 • RAD54L • BARD1 • BRCA • FANCL • PPP2R2A
|
BRCA1 mutation • ATM mutation • PALB2 mutation • CDK12 mutation • BRIP1 mutation • RAD51D mutation • CHEK2 mutation • RAD51C mutation • RAD51B mutation • BARD1 mutation • RAD54L mutation • CHEK1 mutation • CHEK1 expression
|
Trodelvy (sacituzumab govitecan-hziy) • berzosertib (M6620)
Phase 1/2
Yonsei University
Not yet recruiting
Last update posted :
08/31/2021
Initiation :
10/01/2021
Primary completion :
12/31/2022
Completion :
05/31/2023
HER-2 • BRCA1 • BRCA2 • HRD • CDK12 • MLH1 • MSH6 • MSH2 • RAD51B • BRIP1 • CHEK2 • RAD51C • RAD51D • CHEK1 • RAD54L • BARD1 • FANCL • PPP2R2A
|
HER-2 positive • BRCA1 mutation • BRCA2 mutation • ATM mutation • PALB2 mutation • CDK12 mutation • BRIP1 mutation • RAD51D mutation • CHEK2 mutation • RAD51C mutation • RAD51B mutation • BARD1 mutation • CHEK1 mutation • CHEK1 expression
|
Keytruda (pembrolizumab) • Lynparza (olaparib) • paclitaxel
Phase 2
Se-Hoon Lee
Recruiting
Last update posted :
08/25/2021
Initiation :
08/23/2021
Primary completion :
12/31/2022
Completion :
12/31/2022
BRCA1 • BRCA2 • RAD51B • SLFN11 • RAD51 • RAD51C • RAD50 • RAD54L • BRCA • RAD52 • RECQL5 • WRN • NBN • RECQL • RECQL4 • RPA1
|
BRCA1 mutation • BRCA2 mutation • RAD51D mutation • RAD51C mutation • RAD51B mutation • MRE11A mutation • RAD50 mutation • RAD54L mutation • BLM mutation • BRCA mutation • NBN mutation • RAD52 mutation • RECQL mutation • RECQL4 mutation • RECQL5 mutation
|
Lynparza (olaparib) • Avastin (bevacizumab)
Phase 2
West Cancer Center
Not yet recruiting
Last update posted :
08/10/2021
Initiation :
08/01/2021
Primary completion :
08/01/2024
Completion :
08/01/2025
BRCA1 • BRCA2 • HRD • CDK12 • RAD51B • BRIP1 • CHEK2 • RAD51C • RAD51D • CHEK1 • RAD54L • BARD1 • FANCL • PPP2R2A • FANCI
|
BRCA1 mutation • ATM mutation • HRD • PALB2 mutation • BRIP1 mutation • RAD51D mutation • CHEK2 mutation • RAD51C mutation • RAD51B mutation • BARD1 mutation • HRD + BRCA1 mutation • RAD54L mutation • FANCI mutation • RAD51 mutation
|
Zejula (niraparib) • Jemperli (dostarlimab)
Phase 2
Massachusetts General Hospital
Not yet recruiting
Last update posted :
08/05/2021
Initiation :
01/01/2022
Primary completion :
12/01/2024
Completion :
12/01/2026
BRCA1 • BRCA2 • HRD • BAP1 • RAD51B • BRIP1 • RAD51C • RAD50 • RAD54L • BARD1 • PARP1 • XRCC2 • NBN
|
BRCA1 mutation • ATM mutation • HRD • PALB2 mutation • BAP1 mutation • BRIP1 mutation • RAD51D mutation • RAD51C mutation • RAD51B mutation • BARD1 mutation • HRD + BRCA1 mutation • MRE11A mutation • RAD50 mutation • RAD54L mutation • NBN mutation
|
Zejula (niraparib)
Phase 2
Sidney Kimmel Comprehensive Cancer Center at Jo...
Recruiting
Last update posted :
06/07/2021
Initiation :
03/01/2017
Primary completion :
01/01/2022
Completion :
08/01/2022
BRCA1 • BRCA2 • ATM • CDK12 • RAD51B • BRIP1 • CHEK2 • RAD51C • RAD51D • CHEK1 • BARD1 • FANCL • PPP2R2A
|
BRCA1 mutation • ATM mutation • PALB2 mutation • CDK12 mutation • BRIP1 mutation • RAD51D mutation • CHEK2 mutation • RAD51C mutation • RAD51B mutation • BARD1 mutation • CHEK1 mutation • CHEK1 expression
|
Lynparza (olaparib)
Phase 2
University Health Network, Toronto
Recruiting
Last update posted :
04/13/2021
Initiation :
07/19/2016
Primary completion :
06/01/2021
Completion :
12/01/2021
BRCA1 • BRCA2 • PALB2 • RAD51B • BRIP1 • RAD51C • RAD51D • MUC16 • BARD1 • FANCM • PARP1 • PPM1D
|
BRCA1 mutation • BRCA2 mutation • PALB2 mutation • BRIP1 mutation • RAD51D mutation • RAD51C mutation • RAD51B mutation • BARD1 mutation • FANCM mutation • MUC16 expression • PPM1D mutation • RAD51 mutation
|
Lynparza (olaparib)
Phase 2
Clovis Oncology, Inc.
Recruiting
Last update posted :
03/26/2021
Initiation :
11/21/2019
Primary completion :
11/01/2021
Completion :
05/01/2022
BRCA1 • BRCA2 • RAD51B • BRIP1 • FANCA • RAD51 • RAD51C • RAD51D • BARD1 • NBN
|
BRCA1 mutation • PALB2 mutation • BRIP1 mutation • RAD51D mutation • RAD51C mutation • FANCA mutation • RAD51B mutation • BARD1 mutation • FANCA deletion • NBN mutation • RAD51 mutation
|
Rubraca (rucaparib)
Phase 2
Sidney Kimmel Comprehensive Cancer Center at Jo...
Recruiting
Last update posted :
03/15/2021
Initiation :
06/03/2019
Primary completion :
03/01/2022
Completion :
03/01/2023
BRCA1 • BRCA2 • BAP1 • CDK12 • RAD51B • BRIP1 • CHEK2 • RAD51C • RAD51D • CHEK1 • RAD54L • BARD1 • FANCL
|
BRCA1 mutation • ATM mutation • PALB2 mutation • CDK12 mutation • BRIP1 mutation • RAD51D mutation • CHEK2 mutation • RAD51C mutation • RAD51B mutation • BARD1 mutation • RAD54L mutation • CHEK1 mutation • RAD51 mutation • CHEK1 expression
|
Lynparza (olaparib)
Phase 2
Massachusetts General Hospital
Active, not recruiting
Last update posted :
03/12/2021
Initiation :
01/08/2019
Primary completion :
04/30/2022
Completion :
04/30/2025
BRCA1 • BRCA2 • MYC • ATM • ARID1A • CCNE1 • CDK12 • FBXW7 • ATRX • RAD51B • BRIP1 • CHEK2 • FANCA • RAD51C • RAD51D • BARD1 • FANCF • FANCM • NBN • FANCC
|
BRCA1 mutation • BRCA2 mutation • ATM mutation • ARID1A mutation • MYC amplification • CDK12 mutation • CCNE1 amplification • ATRX mutation • BRIP1 mutation • FBXW7 mutation • RAD51D mutation • CHEK2 mutation • RAD51C mutation • FANCA mutation • RAD51B mutation • BARD1 mutation • FANCF mutation • MRE11A mutation • FANCM mutation • NBN mutation
|
berzosertib (M6620)
Phase 2
Samsung Medical Center
Completed
Last update posted :
02/18/2021
Initiation :
08/01/2016
Primary completion :
01/01/2021
Completion :
01/01/2021
BRCA1 • BRCA2 • ATM • RAD51B • RAD51 • RAD51C • RAD50 • RAD54L • RAD52 • RECQL5 • WRN • NBN • RECQL • RECQL4 • RPA1
|
BRCA1 mutation • BRCA2 mutation • RAD51D mutation • RAD51C mutation • RAD51B mutation • MRE11A mutation • RAD50 mutation • RAD54L mutation • BLM mutation • WRN mutation • NBN mutation • RAD52 mutation • RECQL mutation • RECQL4 mutation • RECQL5 mutation • RPA1 mutation
|
Lynparza (olaparib)